Some synergies with the BTK family inhibitor ibrutinib (PCI32765, FDA approved for use against several hematological cancers which also inhibits BMX, a BTK family member expressed in carcinoma52 are also seen. This evidence concerns the gene BMX and hematopoietic and lymphoid cell neoplasm.